<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31838784</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Novel mutation in optineurin causing aggressive ALS+/-frontotemporal dementia.</ArticleTitle><Pagination><StartPage>2377</StartPage><EndPage>2383</EndPage><MedlinePgn>2377-2383</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.50928</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Mutations in optineurin (OPTN) have been identified in familial and sporadic amyotrophic lateral sclerosis (ALS). We screened a cohort of Chinese patients for mutations in optineurin. We also performed an extensive literatures review of all mutations in optineurin identified previously to detect genotype-phenotype associations.</AbstractText><AbstractText Label="METHODS">All 16 exons of the OPTN gene in a cohort of 15 familial ALS indexes and 275 sporadic ALS patients of Chinese origin were sequenced by targeted next generation sequencing.</AbstractText><AbstractText Label="RESULTS">Two known heterozygous missense mutations in the OPTN, c.1481T&gt;&#xa0;G (p.L494W), and c.1546G&gt;&#xa0;C (p.E516Q), as well as one novel heterozygous missense mutation c.1690G&gt;&#xa0;C (p.D564H) were each detected in one sporadic ALS patient. The patient carrying the p.E516Q mutation developed clinical features of ALS-frontotemporal dementia (FTD) and the patient carrying the p.D564H mutation showed a phenotype of ALS. They both had an aggressive course, with a survival of 18 and 14&#xa0;months respectively. Literature review showed that the clinical phenotypes in OPTN mutated ALS were not homogeneous, although some individuals showed a relatively slow progression and a long duration, some mutations carriers developed an aggressive progression and a short survival.</AbstractText><AbstractText Label="INTERPRETATION">OPTN mutations contribute to ALS in Chinese population and account for 0.8% of sporadic ALS patients and 1.5% of familial ALS in the pooled Chinese ALS cohorts. Mutations in optineurin can cause aggressive ALS+/-FTD.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Shu-Man</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurophysiology, Henan Provincial People's Hospital, Zhengzhou, 450003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Che</LastName><ForeName>Chun-Hui</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, 350001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Shu-Yan</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, 450003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chang-Yun</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, 350001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Liu-Yi</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Department of Neurophysiology, Henan Provincial People's Hospital, Zhengzhou, 450003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuan-Xiao</ForeName><Initials>YX</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, 350001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Hua-Pin</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, 350001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Zhang-Yu</ForeName><Initials>ZY</Initials><Identifier Source="ORCID">0000-0002-8277-1110</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, 350001, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81671271</GrantID><Agency>National Natural Science Foundation of China</Agency><Country>International</Country></Grant><Grant><GrantID>2017B014</GrantID><Agency>Program for New Century Excellent Talents in Fujian Province University</Agency><Country>International</Country></Grant><Grant><GrantID>2017Y91010015</GrantID><Agency>Joint Funds for the innovation of science and Technology, Fujian province</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C409460">OPTN protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31838784</ArticleId><ArticleId IdType="pmc">PMC6917321</ArticleId><ArticleId IdType="doi">10.1002/acn3.50928</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk AE, Weishaupt JH, Andersen PM, et al. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med Genet 2018;30:252&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132774</ArticleId><ArticleId IdType="pubmed">30220791</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010;465:223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et al. A revision of the El Escorial criteria &#x2010; 2015. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:291&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S, Ji Y, Li C, et al. The edinburgh cognitive and behavioural ALS screen in a chinese amyotrophic lateral sclerosis population. PLoS ONE 2016;11:e0155496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4873026</ArticleId><ArticleId IdType="pubmed">27195772</ArticleId></ArticleIdList></Reference><Reference><Citation>Soong BW, Lin KP, Guo YC, et al. Extensive molecular genetic survey of Taiwanese patients with amyotrophic lateral sclerosis. Neurobiol Aging 2014;35:e2421&#x2013;2426.</Citation><ArticleIdList><ArticleId IdType="pubmed">24908169</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Liu F, Cui B, et al. Mutation spectrum of Chinese patients with familial and sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2016;87:1272&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">27313233</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Ji Y, Tang L, et al. Optineurin mutations in patients with sporadic amyotrophic lateral sclerosis in China. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:485&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">26503823</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein O, Nayshool O, Nefussy B, et al. OPTN 691_692insAG is a founder mutation causing recessive ALS and increased risk in heterozygotes. Neurology 2016;86:446&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4773945</ArticleId><ArticleId IdType="pubmed">26740678</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozoguz A, Uyan O, Birdal G, et al. The distinct genetic pattern of ALS in Turkey and novel mutations. Neurobiol Aging 2015;36:e1769&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6591733</ArticleId><ArticleId IdType="pubmed">25681989</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller K, Brenner D, Weydt P, et al. Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry 2018;89:817&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">29650794</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotkine M, De Majo M, Wong CH, et al. A novel optineurin truncation mutation identified in a consanguineous Palestinian family with Amyotrophic Lateral Sclerosis confirms loss of function as a disease mechanism. F1000Research 2016;5:2754(poster).</Citation></Reference><Reference><Citation>Beeldman E, van der Kooi AJ, de Visser M, et al. A Dutch family with autosomal recessively inherited lower motor neuron predominant motor neuron disease due to optineurin mutations. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:410&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">26203661</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Rampersaud E, Baker M, et al. Identification of compound heterozygous variants in OPTN in an ALS&#x2010;FTD patient from the CReATe consortium: a case report. Amyotroph Lateral Scler Frontotemporal Degener 2018;19:469&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6116528</ArticleId><ArticleId IdType="pubmed">29558868</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Bo R, Tiloca C, Pensato V, et al. Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011;82:1239&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">21613650</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Conte A, Zollino M, et al. Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease. Neurology 2012;79:66&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">22722621</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan SMK, Gendron TF, Petrucelli LOPTN, et al. p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia. Am J Med Genet B Neuropsychiatr Genet 2018;177:75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">29080331</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama A, Niihori T, Warita H, et al. Comprehensive targeted next&#x2010;generation sequencing in Japanese familial amyotrophic lateral sclerosis. Neurobiol Aging 2017;53:194.e1&#x2010;194.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28160950</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruse H, Takahashi Y, Kihira T, et al. Mutational analysis of familial and sporadic amyotrophic lateral sclerosis with OPTN mutations in Japanese population. Amyotroph Lateral Scler 2012;13:562&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">22708870</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumer Z, Bertelsen B, Gredal O, et al. Novel heterozygous nonsense mutation of the OPTN gene segregating in a Danish family with ALS. Neurobiol Aging 2012;33:e201&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">21852022</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, van Vught PW, van Es MA, et al. Novel optineurin mutations in sporadic amyotrophic lateral sclerosis patients. Neurobiol Aging 2012;33:e1011&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pubmed">21802176</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaupt JH, Waibel S, Birve A, et al. A novel optineurin truncating mutation and three glaucoma&#x2010;associated missense variants in patients with familial amyotrophic lateral sclerosis in Germany. Neurobiol Aging 2013;34:e1519&#x2013;1515.</Citation><ArticleIdList><ArticleId IdType="pubmed">23062601</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal M, Swarup G, Balasubramanian D. Functional analysis of optineurin and some of its disease&#x2010;associated mutants. IUBMB Life 2015;67:120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">25855473</ArticleId></ArticleIdList></Reference><Reference><Citation>Markovinovic A, Cimbro R, Ljutic T, et al. Optineurin in amyotrophic lateral sclerosis: Multifunctional adaptor protein at the crossroads of different neuroprotective mechanisms. Prog Neurogibol 2017;154:1&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">28456633</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>